Answers are grounded in this paper and cite their sources.
Accurate classification of intracranial tumors on contrast-enhanced T1-weighted MRI (CE-T1) is challenged by heterogeneous enhancement patterns and strong correlations among multiple slices from the same patient. We propose a compact CE-T1 MRI analysis framework that standardizes image intensities, enhances local CLAHE (contrast using contrast-limited adaptive histogram equalization), and applies a lightweight convolutional classifier whose slice-level probabilities are aggregated to obtain a single patient-level prediction. An independent optional U-Net-based pathway provides binary tumor segmentation when spatial delineation is required. Evaluation was performed using a strictly patient-wise, leakage-controlled protocol with stratified five-fold cross-validation on 233 subjects (3,064 slices) comprising glioma, meningioma, and pituitary adenoma. The classifier achieved 99.4% patient-level accuracy, with macro-averaged sensitivity and specificity of 99.3% and 99.0%, respectively. The optional segmentation pathway achieved a mean Dice similarity coefficient of 97.3%. Post-hoc temperature scaling reduced the patient-level expected calibration error from 3.0% to approximately 1.2%, although larger independent cohorts are required to determine the stability of this estimate. The classifier contains 7.8 million parameters and requires approximately 15.9 GFLOPs per 256× 256 slice, with an end-to-end inference latency of approximately 0.41 s per slice under the evaluated hardware configuration. These findings demonstrate strong patient-level performance within the evaluated retrospective cohort. The framework is intended as a research-stage approach for reproducible evaluation rather than a clinically validated diagnostic system for routine radiology practice. However, no independent quantitative external validation was performed; therefore, multi-centre evaluation across different scanners, acquisition protocols, institutions, and patient populations is required before generalizability or clinical applicability can be established.
No takes yet. Share an insight, caveat, or question.
Asiri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: